Special Issue

Topic: Targeted Cancer Therapy

A Special Issue of Cancer Drug Resistance

ISSN 2578-532X (Online)

Submission deadline: 3 Sep 2018

Guest Editor(s)

Dr. Elisa Giovannetti, MD, PhD
Lab Medical Oncology, VU University Medical Center (VUmc), Cancer Center Amsterdam, The Netherlands.
Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.
Dr. Jose Antonio Rodriguez, PhD
Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine and Nursing) of the University of the Basque Country (UPV/EHU), Basque Country, Spain.

Special Issue Introduction

Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells. A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib, an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia. Over the last years, significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases, but also other protein families and cellular processes. Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies, such as lung cancer.
The Special Issue of "Targeted Cancer Therapy" will include Reviews and Commentaries updating the clinical use of targeted agents in the treatment of different tumor types, and the mechanisms that underlie the action of drugs directed to different types of targets. The Special Issue will also include Research articles presenting novel outstanding data on all aspects of targeted cancer therapy. All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.

Keywords

Biomarkers, personalized medicine, new approaches to cancer treatment, molecularly targeted drugs, mechanisms of targeted drugs, resistance to targeted therapies, novel targets

Submission Deadline

3 Sep 2018

Submission Information

For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr
Submission Deadline: 3 Sep 2018
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com

Published Articles

Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Open Access Review
Views: Downloads:
Download PDF
Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents
Open Access Review
Views: Downloads:
Download PDF
Glutamine metabolism in cancer therapy
Open Access Review
Views: Downloads:
Download PDF
Targeted therapies in cancer: where are we going?
Open Access Editorial
Views: Downloads:
Download PDF
Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/